| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 2.5 | 2.3 |
| Gross profit | 1.1 | 0.9 |
| Profit before tax | -0.1 | -0.3 |
| Net income | -0.1 | -0.3 |
| EPS (diluted, $ a share) | $-0.03 | $-0.10 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +11.7% |
|---|---|
| Gross margin | 43.2% |
| Operating margin | -2.0% |
10-Q filed with the SEC, OTC: LCTC. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Lifeloc Technologies, Inc: key numbers
- Share price
- $3.09Close, Nov 16
- Market cap
- $8.51M
- Shares outstanding
- 2.75MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Laboratory Analytical InstrumentsSIC 3826
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Lifeloc Technologies, Inc
All →Lifeloc Technologies Financial Results
Lifeloc Technologies reported Q3 2026 net revenue of $2.522 million, a 12% increase year-over-year, and a narrowed net loss of $85 thousand. The company highlighted margin improvements from price increases and continued heavy R&D investment in its SpinDetect drug analyzer platform, which is entering beta testing.
- Term
- Q3 2026
Lifeloc Technologies Investor Presentation
Lifeloc Technologies announced its participation in the Lytham Partners Fall 2026 Investor Conference, featuring a virtual webcast presentation and one-on-one investor meetings. Management intends to provide a business update on its breath alcohol testing operations and the development status of its SpinDetect Analyzer for rapid drug testing.
- Counterparty
- Lytham Partners
- Earnings call
- Sep 29, 2026, 2:45 PM ET